A STUDY OF ROACTEMRA/ACTEMRA (TOCILIZUMAB) IN TOCILIZUMAB-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO NON-BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) OR BIOLOGIC THERAPY: